Prediction of CR following a second course of '7+3' in patients with newly diagnosed acute myeloid leukemia not in CR after a first course

Leukemia. 2016 Aug;30(8):1779-80. doi: 10.1038/leu.2016.48. Epub 2016 Feb 29.

Authors

M Othus¹, S Mukherjee², M A Sekeres², J Godwin³, S Petersdorf⁴, F R Appelbaum¹, H Erba⁵, E Estey¹

Affiliations

¹ Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
² Leukemia Program, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH, USA.
³ Earle A. Chiles Research Institute, Providence Cancer Center, Portland, OR, USA.
⁴ Seattle Genetics, Seattle, WA, USA.
⁵ Division of Hematology & Oncology, University of Alabama, Birmingham, AL, USA.

No abstract available

Publication types

Letter

MeSH terms

Adult
Aged
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
Cytarabine / administration & dosage
Daunorubicin / administration & dosage
Female
Guideline Adherence / statistics & numerical data*
Humans
Idarubicin / administration & dosage
Leukemia, Myeloid, Acute / drug therapy*
Male
Middle Aged
Practice Guidelines as Topic

Substances

Cytarabine
Idarubicin
Daunorubicin

Grants and funding